On May 31, 2018 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference at 12:30 pm EDT on Friday, June 8, 2018, in New York, NY (Press release, Tracon Pharmaceuticals, MAY 31, 2018, View Source [SID1234527008]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentation" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

On May 31, 2018 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Raul Rodriguez, the company’s president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018 at 10:30am EDT (Press release, Rigel, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352484 [SID1234527005]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

On May 31, 2018 Polaris Group reported that the first patient has been dosed in a phase 2 trial of ADI‑PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University (Press release, Polaris Pharmaceuticals, MAY 31, 2018, View Source [SID1234527003]). In addition to a global phase 2/3 study in malignant plural mesothelioma featuring ADI‑PEG 20 in combination with pemetrexed and cisplatin and a global phase 2 study in hepatocellular carcinoma featuring ADI‑PEG 20 in combination with FOLFOX, Polaris Group is currently conducting multiple phase 1 clinical trials, including ADI‑PEG 20 in combination with pembrolizumab in solid tumors, in combination with low dose cytarabine for acute myeloid leukemia in older patients, and in combination with atezolizumab, pemetrexed and cisplatin in non-small cell lung carcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very excited to partner with Polaris to bring metabolic therapies to the field of rare tumors", said the lead investigator Brian Van Tine, M.D., Ph.D., Associate Professor of Medicine and Sarcoma Program Director at Barnes and Jewish Hospital, Washington University in St. Louis.

About ADI-PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.

On May 31, 2018 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) reported that Dave Stack, chairman and chief executive officer, will present at the Jefferies 2018 Healthcare Conference at 9:30 AM ET on Tuesday, June 5, 2018 (Press release, Pacira Pharmaceuticals, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352482 [SID1234527001]). Live audio of the presentation can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 31, 2018 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will be presenting at two upcoming investor conferences (Press release, Myriad Genetics, MAY 31, 2018, View Source [SID1234527000]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 12, 2018, Mark C. Capone, president and CEO, will present at the 39th Annual Goldman Sachs Healthcare Conference in Palos Verdes, California at 4:00 p.m. ET.

On June 13, 2018, R. Bryan Riggsbee, chief financial officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois at 3:40 p.m. ET.

The presentations will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.